New immune therapy tested for rare HIV-Linked cancer
NCT ID NCT05646082
Summary
This early-stage study is testing the safety of a drug called dostarlimab for people with HIV and a rare, treatment-resistant cancer called Kaposi sarcoma. Dostarlimab is an immunotherapy designed to help the body's own immune system fight cancer cells. The study will enroll up to 20 adults to see how well they tolerate the drug and gather early signs of its effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HIV ASSOCIATED KAPOSI SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chelsea & Westminster Hospital
London, SW10 9NH, United Kingdom
Conditions
Explore the condition pages connected to this study.